Treating Flares vs. Chronic Dry Eye Disease

Preeya K. Gupta, MD

Founder and Director of Triangle Eye Consultants

Wake Forest and Cary, North Carolina

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, New York

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Preeya K. Gupta, MD, has no financial agreements with commercial interests.

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan , Alcon Vision, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharma, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus Therapeutics.  Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

 EDITORIAL SUPPORT DISCLOSURES The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.